{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:21:15Z","timestamp":1739424075698,"version":"3.37.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.09.009","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T21:44:03Z","timestamp":1727127843000},"page":"156-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2024.09.009_bib0001","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clml.2024.09.009_bib0002","first-page":"1267","article-title":"Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study","volume":"66","author":"Bonnet","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1016\/j.clml.2024.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.V51.6.1005.1005","article-title":"Unmaintained remissions in multiple myeloma","volume":"51","author":"Alexanian","year":"1978","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-93-3-399","article-title":"Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma","volume":"93","author":"Gutterman","year":"1980","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.clml.2024.09.009_bib0005","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0308-2261(21)00328-3","article-title":"Interferon treatment for multiple myeloma","volume":"11","author":"Alexanian","year":"1982","journal-title":"Clin Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0006","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/1096-8652(200011)65:3<204::AID-AJH5>3.0.CO;2-H","article-title":"Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma","volume":"65","author":"Alexanian","year":"2000","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.V62.3.572.572","article-title":"Prednisone pulse therapy for refractory myeloma","volume":"62","author":"Alexanian","year":"1983","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.09.009_bib0008","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0009","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1172\/JCI111056","article-title":"Marrow cytometry and prognosis in myeloma","volume":"72","author":"Barlogie","year":"1983","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.clml.2024.09.009_bib0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0002-9343(86)90625-X","article-title":"Biclonal and hypodiploid multiple myeloma","volume":"80","author":"Smith","year":"1986","journal-title":"Am J Med"},{"issue":"21","key":"10.1016\/j.clml.2024.09.009_bib0011","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198405243102104","article-title":"Effective treatment of advanced multiple myeloma refractory to alkylating agents","volume":"310","author":"Barlogie","year":"1984","journal-title":"N Engl J Med"},{"issue":"8354","key":"10.1016\/j.clml.2024.09.009_bib0012","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2024.09.009_bib0013","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","article-title":"High-dose melphalan with autologous bone marrow transplantation for multiple myeloma","volume":"67","author":"Barlogie","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.009_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/916479","article-title":"Curability of multiple myeloma","volume":"2012","author":"Alexanian","year":"2012","journal-title":"Bone Marrow Res"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"56","author":"Alexanian","year":"1980","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.09.009_bib0016","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.09.009_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.09.009_bib0018","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","article-title":"Prognostic features of asymptomatic multiple myeloma","volume":"97","author":"Weber","year":"1997","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.09.009_bib0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.09.009_bib0020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ajh.2830200405","article-title":"Beta 2 microglobulin in multiple myeloma","volume":"20","author":"Alexanian","year":"1985","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.clml.2024.09.009_bib0021","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","article-title":"High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma","volume":"115","author":"Dimopoulos","year":"1991","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.clml.2024.09.009_bib0022","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1001\/archinte.1990.00040031693017","article-title":"Renal failure in multiple myeloma. Pathogenesis and prognostic implications","volume":"150","author":"Alexanian","year":"1990","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.clml.2024.09.009_bib0023","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.1993.11.7.1311","article-title":"Magnetic resonance imaging in the staging of solitary plasmacytoma of bone","volume":"11","author":"Moulopoulos","year":"1993","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.09.009_bib0024","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1148\/radiology.193.2.7972760","article-title":"Multiple myeloma: MR patterns of response to treatment","volume":"193","author":"Moulopoulos","year":"1994","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.clml.2024.09.009_bib0025","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/028418600750063578","article-title":"Imaging of myeloma bone disease\u2013implications for staging, prognosis and follow-up","volume":"39","author":"Dimopoulos","year":"2000","journal-title":"Acta Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.09.009_bib0026","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/archinte.1985.00360110149029","article-title":"Ten-year survival in multiple myeloma","volume":"145","author":"Alexanian","year":"1985","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0027","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/bmt.2009.176","article-title":"CR represents an early index of potential long survival in multiple myeloma","volume":"45","author":"Wang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.09.009_bib0028","series-title":"Oncologic Drugs Advisory Committee (ODAC) Meeting","article-title":"ODAC unanimously votes in favor of MRD tesing as an early endpoint in Myeloma Clinical Trials to support accelerated approvals of new treatments","author":"ODAC","year":"2024"},{"issue":"21","key":"10.1016\/j.clml.2024.09.009_bib0029","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.09.009_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.09.009_bib0031","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","article-title":"Thalidomide and dexamethasone for resistant multiple myeloma","volume":"121","author":"Anagnostopoulos","year":"2003","journal-title":"Br J Haematol"},{"issue":"26","key":"10.1016\/j.clml.2024.09.009_bib0032","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.09.009_bib0033","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","article-title":"Myeloma protein kinetics following chemotherapy","volume":"60","author":"McLaughlin","year":"1982","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.09.009_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V31.1.1.1","article-title":"Melphalan therapy for plasma cell myeloma","volume":"31","author":"Alexanian","year":"1968","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.09.009_bib0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-118-3-199302010-00007","article-title":"Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine","volume":"118","author":"Dimopoulos","year":"1993","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.clml.2024.09.009_bib0036","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.09.009_bib0037","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstrom's macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402353X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502402353X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:47:08Z","timestamp":1739364428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502402353X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S215226502402353X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of Curability","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}